These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 32609812)

  • 21. Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.
    Lazaridis L; Schäfer N; Teuber-Hanselmann S; Blau T; Schmidt T; Oster C; Weller J; Tzaridis T; Pierscianek D; Keyvani K; Kleinschnitz C; Stuschke M; Scheffler B; Deuschl C; Sure U; Herrlinger U; Kebir S; Glas M
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):787-792. PubMed ID: 31828428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How did lomustine become standard of care in recurrent glioblastoma?
    Weller M; Le Rhun E
    Cancer Treat Rev; 2020 Jul; 87():102029. PubMed ID: 32408220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
    Brandes AA; Carpentier AF; Kesari S; Sepulveda-Sanchez JM; Wheeler HR; Chinot O; Cher L; Steinbach JP; Capper D; Specenier P; Rodon J; Cleverly A; Smith C; Gueorguieva I; Miles C; Guba SC; Desaiah D; Lahn MM; Wick W
    Neuro Oncol; 2016 Aug; 18(8):1146-56. PubMed ID: 26902851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A troublesome burden, the amplification of EGFR in glioblastoma!
    Lobbous M; Nabors LB
    Neuro Oncol; 2020 May; 22(5):594-595. PubMed ID: 32144420
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
    Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
    Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Lomustine and temozolomide in combination with radiotherapy : New treatment option for patients with MGMT promoter methylated Glioblastoma].
    Seidel C; Kortmann RD
    Strahlenther Onkol; 2019 Sep; 195(9):855-856. PubMed ID: 31243475
    [No Abstract]   [Full Text] [Related]  

  • 27. Reverse swing-M, phase 1 study of repurposing mebendazole in recurrent high-grade glioma.
    Patil VM; Bhelekar A; Menon N; Bhattacharjee A; Simha V; Abhinav R; Abhyankar A; Sridhar E; Mahajan A; Puranik AD; Purandare N; Janu A; Ahuja A; Krishnatry R; Gupta T; Jalali R
    Cancer Med; 2020 Jul; 9(13):4676-4685. PubMed ID: 32400117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lomustine-temozolomide combination efficacious in newly diagnosed glioblastoma.
    Killock D
    Nat Rev Clin Oncol; 2019 May; 16(5):273. PubMed ID: 30809028
    [No Abstract]   [Full Text] [Related]  

  • 29. A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.
    Robins HI; Zhang P; Gilbert MR; Chakravarti A; de Groot JF; Grimm SA; Wang F; Lieberman FS; Krauze A; Trotti AM; Mohile N; Kee AY; Colman H; Cavaliere R; Kesari S; Chmura SJ; Mehta M
    J Neurooncol; 2016 Jan; 126(2):309-16. PubMed ID: 26508094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin.
    Gan HK; Parakh S; Lassman AB; Seow A; Lau E; Lee ST; Ameratunga M; Perchyonok Y; Cao D; Burvenich IJG; O'Keefe GJ; Rigopoulos A; Gomez E; Maag D; Scott AM
    Neurooncol Adv; 2021; 3(1):vdab102. PubMed ID: 34549181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
    Gorlia T; van den Bent MJ; Hegi ME; Mirimanoff RO; Weller M; Cairncross JG; Eisenhauer E; Belanger K; Brandes AA; Allgeier A; Lacombe D; Stupp R
    Lancet Oncol; 2008 Jan; 9(1):29-38. PubMed ID: 18082451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
    Stupp R; Taillibert S; Kanner A; Read W; Steinberg D; Lhermitte B; Toms S; Idbaih A; Ahluwalia MS; Fink K; Di Meco F; Lieberman F; Zhu JJ; Stragliotto G; Tran D; Brem S; Hottinger A; Kirson ED; Lavy-Shahaf G; Weinberg U; Kim CY; Paek SH; Nicholas G; Bruna J; Hirte H; Weller M; Palti Y; Hegi ME; Ram Z
    JAMA; 2017 Dec; 318(23):2306-2316. PubMed ID: 29260225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.
    Duerinck J; Du Four S; Bouttens F; Andre C; Verschaeve V; Van Fraeyenhove F; Chaskis C; D'Haene N; Le Mercier M; Rogiers A; Michotte A; Salmon I; Neyns B
    J Neurooncol; 2018 Jan; 136(1):115-125. PubMed ID: 28988341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective study on glioblastoma in the elderly.
    Brandes AA; Vastola F; Basso U; Berti F; Pinna G; Rotilio A; Gardiman M; Scienza R; Monfardini S; Ermani M
    Cancer; 2003 Feb; 97(3):657-62. PubMed ID: 12548608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
    Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J
    Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma.
    Kocher M; Frommolt P; Borberg SK; Rühl U; Steingräber M; Niewald M; Staar S; Stuschke M; Becker G; Fischedick AR; Herfarth K; Grauthoff H; Müller RP
    Strahlenther Onkol; 2008 Nov; 184(11):572-9. PubMed ID: 19016015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine.
    Wenger KJ; Wagner M; You SJ; Franz K; Harter PN; Burger MC; Voss M; Ronellenfitsch MW; Fokas E; Steinbach JP; Bähr O
    Oncol Lett; 2017 Jul; 14(1):1141-1146. PubMed ID: 28693286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
    Herrlinger U; Rieger J; Koch D; Loeser S; Blaschke B; Kortmann RD; Steinbach JP; Hundsberger T; Wick W; Meyermann R; Tan TC; Sommer C; Bamberg M; Reifenberger G; Weller M
    J Clin Oncol; 2006 Sep; 24(27):4412-7. PubMed ID: 16983109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma.
    Gilbert MR; Pugh SL; Aldape K; Sorensen AG; Mikkelsen T; Penas-Prado M; Bokstein F; Kwok Y; Lee RJ; Mehta M
    J Neurooncol; 2017 Jan; 131(1):193-199. PubMed ID: 27770279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia.
    Mabasa VH; Taylor SC
    J Oncol Pharm Pract; 2006 Jun; 12(2):105-11. PubMed ID: 16984749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.